EUCTR2007-004888-22-FRActive, not recruitingNot Applicable
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapies. - CHCD122A2103
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- ovartis Pharma AG
- Enrollment
- 230
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients must have confirmed diagnosis, according to the Revised European American Lymphoma/World Health Organization [REAL/WHO] classification, of the following B-cell lymphomas:
- •1.Follicular lymphoma (FL)
- •2.Marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT)
- •3.Diffuse large B-cell lymphoma (DLBCL)
- •4.Mantle cell lymphoma (MCL), OR
- •5.Hodgkin lymphoma (HL)
- •Patients must have progressed after at least 2 prior therapies (autologous stem cell transplantation is considered as 1 therapy):
- •1.Patient must receive at least one prior therapy with a rituximab containing regimen
- •2.If patient received autologous stem cell transplantation, patient must have received at least 1 prior systemic therapy
- •3.If patient did not receive autologous stem cell transplantation, patient must have received at least 2 prior systemic therapies
- •Patients who received autologous stem cell transplantation:
- •1.Must be at least 12 weeks post-transplant prior to study drug, AND
- •2.Must have recovered fully from the side effects of such treatment prior to beginning study treatment.
- •Patients who have NOT received autologous stem cell transplantation:
- •1.Must be ineligible for the autologous stem cell transplantation, OR
- •2.If eligible, patients chose not to receive stem cell transplant
- •Patients must have discontinued any previous anticancer and investigational therapy including radiation therapy for at least 21 days prior to study drug, and must have recovered fully from the side effects of such treatment prior to beginning study drug.
- •Patients must have discontinued any previous monoclonal antibody or radioimmunotherapy administration for at least 60 days prior to study drug, and are confirmed either have no response to that therapy or have disease progression after the treatment. Patients must have recovered fully from the side effects of that treatment prior to beginning study treatment.
- •Patients must not have undergone major surgery within 30 days prior to study drug, and must have recovered fully from the side effects of any major or minor surgical procedures prior to study treatment.
- •Patients must be > 18 years
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Patients who have been treated with any anti-CD40 antibody
- •Patients who have received prior allogeneic stem cell transplant
- •Patients who have had a prior anaphylactic or other severe infusion reaction such that the patient is unable to tolerate human immunoglobulin or monoclonal antibody administration
- •Patients who are taking systemic corticosteroids, except for a dose up to 100 mg of hydrocortisone or equivalent as premedication administered prior to certain medications or blood products
- •Patients who have current drug or alcohol abuse
- •Patients who have history or clinical evidence of central nervous system, meningeal, or epidural disease including brain metastasis
- •Impaired cardiac function or clinically significant cardiac disease, including any one of the following:
- •1.New York Heart Association Class III or IV cardiac disease, including preexisting clinically significant arrhythmia, congestive heart failure, or cardiomyopathy
- •2.Angina pectoris = 3 months prior to starting study drug
- •3.Acute MI = 3 months prior to starting study drug
- •4.Other clinically significant heart disease (e.g., uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
- •Patients who have history of pancreatic disease (e.g., acute or chronic pancreatitis, etc.) or any surgery of the pancreas
- •Patients who have gallbladder stone, cystic fibrosis, or any other risk factors that may increase the risk of pancreatitis
- •Patients who have history of active infection (viral, bacterial, or fungal) requiring systemic therapy within 4 weeks prior to enrollment. Prophylactic antibiotics and anti-viral therapies are permitted
Investigators
Similar Trials
Active, not recruiting
Phase 1
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103EUCTR2007-004888-22-BEovartis Pharma AG230
Active, not recruiting
Not Applicable
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at least two prior therapiesEUCTR2007-004888-22-DEovartis Pharma Services AG230
Active, not recruiting
Phase 1
A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin's or Hodgkin's lymphoma who have progressed after at leastr two prior therapies - CHCD122A2103EUCTR2007-004888-22-GBovartis Pharma Services AG
Active, not recruiting
Not Applicable
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 17.1Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: PTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-BEovartis Pharma AG91
Active, not recruiting
Phase 1
An interventional study of the combination of MEK162 plus AMG 479 (ganitumab) in adult patients with selected advanced solid tumorscolorectal adenocarcinoma.metastatic pancreatic adenocarcinomamelanomaMedDRA version: 15.0Level: LLTClassification code 10033599Term: Pancreatic adenocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10052360Term: Colorectal adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 15.0Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000305-76-FRovartis Pharma AG91